Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Unlimited Watchlists, Portfolios, Screeners, and other Barchart tools. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Denali Therapeutics Inc (DNLI)

Denali Therapeutics Inc (DNLI)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Denali (DNLI) Lags Q3 Earnings Estimates, Pipeline in Focus

Denali (DNLI) posts a wider Q3 loss. Collaboration revenues decline year over year.

SNY : 45.87 (+0.72%)
BIIB : 291.41 (-0.17%)
DNLI : 30.18 (+4.68%)
Denali Therapeutics Inc. (DNLI) Reports Q3 Loss, Lags Revenue Estimates

Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of -1.20% and 64.61%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?...

DNLI : 30.18 (+4.68%)
TNGX : 7.22 (+2.85%)
Why Denali Therapeutics' Stock Rose 6.6% on Wednesday

The biopharmaceutical stock was actually up as much as 12.4% before falling a bit at the close.

DNLI : 30.18 (+4.68%)
TAK : 14.50 (-0.34%)
Here's Why You Should Add Intra-Cellular Therapeutics (ITCI) Stock Now

Intra-Cellular's (ITCI) product revenues are primarily driven by higher sales of its schizophrenia and bipolar disorder drug Caplyta. Caplyta is also being evaluated for other CNS indications.

BMRN : 97.12 (-1.56%)
INCY : 77.80 (-0.04%)
ITCI : 52.85 (+1.32%)
DNLI : 30.18 (+4.68%)
Cellarity Announces Close of $121 Million Series C Financing

Cellarity , a life sciences company founded by Flagship Pioneering to transform the way medicines are created, announced today the completion of a $121 million Series C financing, bringing its total funding...

DNLI : 30.18 (+4.68%)
EVLO : 1.9400 (-2.51%)
FHTX : 6.73 (-6.66%)
MRNA : 173.15 (-1.27%)
OMGA : 6.71 (+0.15%)
RUBY : 0.2071 (-2.36%)
SANA : 4.71 (+1.07%)
MCRB : 6.65 (-5.67%)
Denali Therapeutics Inc. (DNLI) Moves 17.7% Higher: Will This Strength Last?

Denali Therapeutics Inc. (DNLI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price...

DNLI : 30.18 (+4.68%)
ZYME : 7.71 (-1.53%)
Why Is Denali Therapeutics Inc. (DNLI) Down 27.4% Since Last Earnings Report?

Denali Therapeutics Inc. (DNLI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

DNLI : 30.18 (+4.68%)
Cellarity Releases Novel, Open-Source, Single-Cell Dataset and Invites the Machine Learning and Computational Biology Communities to Develop New Algorithms Capable of Learning Fundamental Rules of Cell Behavior

Cellarity , a life sciences company founded by Flagship Pioneering to transform the way medicines are created, announced today the release of a unique single-cell dataset to accelerate innovation in mapping...

DNLI : 30.18 (+4.68%)
EVLO : 1.9400 (-2.51%)
FHTX : 6.73 (-6.66%)
MRNA : 173.15 (-1.27%)
OMGA : 6.71 (+0.15%)
RUBY : 0.2071 (-2.36%)
SANA : 4.71 (+1.07%)
MCRB : 6.65 (-5.67%)
Denali (DNLI) Q2 Earnings Beat, Pipeline Progress in Focus

Denali (DNLI) incurs narrower-than-expected Q2 loss while collaboration revenues beat estimates.

SNY : 45.87 (+0.72%)
BIIB : 291.41 (-0.17%)
DNLI : 30.18 (+4.68%)
Denali Therapeutics Inc. (DNLI) Reports Q2 Loss, Tops Revenue Estimates

Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of 7.69% and 15.73%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

DNLI : 30.18 (+4.68%)
CDTX : 0.6770 (-4.65%)

Barchart Exclusives

3 Option Ideas To Consider This Wednesday
Today, we are using some moving average filters to find bullish stocks and then looking at a couple of different trade ideas. Read more

Barchart Futures Commentary

Barchart Futures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar